CD274 and non-small cell lung carcinoma: For example, the IMpower 010 study showed that atezolizumab as postoperative adjuvant therapy showed significant long-term benefit and prolonged DFS in patients with stage IB-IIIA NSCLC with high PD-L1 expression (39).